DUSA Pharmaceuticals, Inc. reported that Stiefel Laboratories, Inc., DUSA's marketing partner for Latin America, has been informed by ANVISA, the Brazilian drug regulatory authorities, that the Levulan Kerastick has been approved in Brazil. With DUSA's support, Stiefel Laboratories completed the regulatory filing with ANVISA during the second quarter of this year.

Robert Doman, DUSA's president and COO, stated "We are very pleased with the joint efforts between the two companies and progress that has been made since the signing of our agreement with Stiefel Laboratories in January. This represents a significant step in our goal of expanding the distribution of Levulan PDT beyond the North American market." Additional launches are expected to follow in a number of other Latin American countries, subject to regulatory approvals.

DUSA Pharmaceuticals, Inc. is an integrated dermatology specialty pharmaceutical company focused primarily on the development and marketing of its Levulan Photodynamic Therapy (PDT) technology platform, and complementary dermatology products. Levulan PDT is currently approved for the treatment of pre-cancerous actinic keratoses, and is being developed for the treatment of acne and photodamage. DUSA's other dermatology products include Nicomide, and the AVAR line, resulting from its acquisition of Sirius Laboratories, Inc.